A Phase 2 Randomized Double-Blind Placebo-controlled Pilot Study to Assess the Effects of RM-493 a Melanocortin 4 Receptor (MC4R) Agonist in Obese Subjects with Prader-Willi Syndrome (PWS) on Safety Weight Reduction and Food-Related Behaviors